Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300609 · ClinicalTrials.gov registry record · Phase 3
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
A Phase 3 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT03300609 is a Phase 3 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 4 participants.
The verdict
NCT03300609, a Phase 3 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
This randomized trial studies how well panitumumab, leucovorin calcium, and fluorouracil after combination chemotherapy and panitumumab induction work in treating patients with RAS wild type colorectal cancer that has spread from where it started to nearby tissue or lymph nodes or other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as panitumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab, leucovorin calcium, and fluorouracil after combination chemotherapy and panitumumab induction may work better in treating patients with colorectal cancer.
Interventions
- DRUG Capecitabine
- DRUG Fluorouracil
- DRUG Oxaliplatin
- BIOLOGICAL Panitumumab
- DRUG Leucovorin Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2019-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300609
The ClinicalTrials.gov registry entry for NCT03300609 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT03300609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03300609 about?
NCT03300609 is a clinical study titled "5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab". This randomized trial studies how well panitumumab, leucovorin calcium, and fluorouracil after combination chemotherapy and panitumumab induction work in treating patients with RAS wild type colorectal cancer that has spread from where it started to nearby tissue or lymph nodes or other places in th...
What is the current status of trial NCT03300609?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2018-02-27. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT03300609?
The interventions under investigation include: Capecitabine (DRUG), Fluorouracil (DRUG), Oxaliplatin (DRUG), Panitumumab (BIOLOGICAL), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT03300609?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.